Potential Future Pharmacological Treatment of Bladder Dysfunction.

Area of Science:

• Urology
• Pharmacology
• Neuroscience

Background:

• Overactive bladder (OAB) treatments have advanced with antimuscarinics, mirabegron, tadalafil, and botulinum toxin.
• Exploring novel therapeutic pathways is crucial for managing OAB symptoms effectively.
• Current research focuses on understanding the physiological mechanisms underlying bladder dysfunction.

Purpose of the Study:

• To review emerging therapeutic strategies for overactive bladder (OAB).
• To evaluate the potential of novel drug targets, including P2X3 receptor antagonists, endocannabinoid system modulators, and TRP channel inhibitors.
• To assess the translational efficacy of these strategies from animal models to human clinical application.

Main Methods:

• Review of preclinical and clinical studies on novel OAB therapeutic targets.
• Analysis of the role of ATP, endocannabinoids, and transient receptor potential (TRP) channels in bladder function.
• Evaluation of the potential and limitations of P2X3 receptor antagonists, fatty acid amide hydrolase inhibitors, and TRP channel antagonists.

Main Results:

• P2X3 receptor antagonists show promise in animal models but require human validation.
• Endocannabinoid system modulation via fatty acid amide hydrolase inhibitors is a potential approach, with limited clinical data in OAB.
• TRP channels (TRPV1, TRPV2, TRPV4, TRPM8, TRPA1) are implicated in bladder function, but their roles and antagonist development face challenges like adverse effects.

Conclusions:

• Novel therapeutic avenues for OAB are being explored, targeting purinergic, endocannabinoid, and TRP channel pathways.
• Translational research is essential to confirm the efficacy and safety of these emerging treatments in humans.
• Further investigation is needed to overcome challenges and establish the clinical utility of these new drug principles for overactive bladder.